表紙
市場調査レポート

アテローム性動脈硬化症:パイプライン製品の分析

Atherosclerosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232865
出版日 ページ情報 英文 264 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
アテローム性動脈硬化症:パイプライン製品の分析 Atherosclerosis - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 264 Pages
概要

アテローム性動脈硬化症は、プラークが蓄積することで動脈が肥厚し硬化する疾患です。血流を阻害し、深刻な心血管障害を引き起こします。症状は胸痛、四肢または動脈が閉塞した箇所の痛み、息切れ、疲労感、意識障害、血流不足による足の筋力低下などです。

当レポートでは、アテローム性動脈硬化症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アテローム性動脈硬化症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アテローム性動脈硬化症:企業で開発中の治療薬

アテローム性動脈硬化症:大学/機関で研究中の治療薬

アテローム性動脈硬化症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

アテローム性動脈硬化症:企業で開発中の製品

アテローム性動脈硬化症:大学/機関で研究中の製品

アテローム性動脈硬化症の治療薬開発に従事している企業

  • Ache Laboratorios Farmaceuticos S/A
  • advanceCor GmbH
  • AFFiRiS AG
  • Amgen Inc.
  • Arisaph Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • AtheroNova Inc.
  • Bayer AG
  • Campus Technologies Freiburg GmbH
  • Cardax Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx, Inc.
  • CohBar, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • DoNatur GmbH
  • Dybly AG
  • Exicure, Inc.
  • GenKyoTex S.A.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • KineMed, Inc.
  • 興和
  • La Jolla Pharmaceutical Company
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • MI.TO. Technology S.r.L.
  • Omeros Corporation
  • OPKO Health, Inc.
  • 大塚ホールディングス
  • Resverlogix Corp.
  • The Medicines Company
  • Therapix Biosciences Ltd
  • Tolerys SA
  • Vascular Biogenics Ltd.
  • Vericel Corporation
  • Vitae Pharmaceuticals, Inc.
  • XBiotech USA, Inc.

アテローム性動脈硬化症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アテローム性動脈硬化症:最近のパイプライン動向

アテローム性動脈硬化症:休止中のプロジェクト

アテローム性動脈硬化症:開発が中止された製品

アテローム性動脈硬化症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7993IDB

Summary

Global Markets Direct's, 'Atherosclerosis - Pipeline Review, H1 2016', provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
  • The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects
  • The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atherosclerosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atherosclerosis Overview
  • Therapeutics Development
    • Pipeline Products for Atherosclerosis - Overview
    • Pipeline Products for Atherosclerosis - Comparative Analysis
  • Atherosclerosis - Therapeutics under Development by Companies
  • Atherosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Atherosclerosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Atherosclerosis - Products under Development by Companies
  • Atherosclerosis - Products under Investigation by Universities/Institutes
  • Atherosclerosis - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • advanceCor GmbH
    • AFFiRiS AG
    • Amgen Inc.
    • Arisaph Pharmaceuticals, Inc.
    • Artery Therapeutics, Inc.
    • AstraZeneca Plc
    • Athera Biotechnologies AB
    • AtheroNova Inc.
    • Bayer AG
    • Campus Technologies Freiburg GmbH
    • Cardax Pharmaceuticals, Inc.
    • Cerenis Therapeutics Holding SA
    • ChemoCentryx, Inc.
    • CohBar, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • DoNatur GmbH
    • Dybly AG
    • Exicure, Inc.
    • GenKyoTex S.A.
    • Jenrin Discovery, Inc.
    • Johnson & Johnson
    • KineMed, Inc.
    • Kowa Company, Ltd.
    • La Jolla Pharmaceutical Company
    • Lead Discovery Center GmbH
    • Merck & Co., Inc.
    • MI.TO. Technology S.r.L.
    • Omeros Corporation
    • OPKO Health, Inc.
    • Otsuka Holdings Co., Ltd.
    • Resverlogix Corp.
    • The Medicines Company
    • Therapix Biosciences Ltd
    • Tolerys SA
    • Vascular Biogenics Ltd.
    • Vericel Corporation
    • Vitae Pharmaceuticals, Inc.
    • XBiotech USA, Inc.
  • Atherosclerosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AEM-28 - Drug Profile
    • AG-01 - Drug Profile
    • AHRO-001 - Drug Profile
    • AHRO-002 - Drug Profile
    • AHRO-003 - Drug Profile
    • AM-0010 - Drug Profile
    • anacetrapib - Drug Profile
    • Annexin A-5 - Drug Profile
    • apabetalone - Drug Profile
    • APTA-5278 - Drug Profile
    • ARI-1778 - Drug Profile
    • Artpep-2 - Drug Profile
    • ATH-04 - Drug Profile
    • ATH-06 - Drug Profile
    • AZ-876 - Drug Profile
    • BAY-606583 - Drug Profile
    • BSN-272 - Drug Profile
    • CCX-771 - Drug Profile
    • CDX-085 - Drug Profile
    • Cell Therapy for Atherosclerosis - Drug Profile
    • Cellular Immunotherapy for Atherosclerosis - Drug Profile
    • CER-209 - Drug Profile
    • CM-7 - Drug Profile
    • COR-2 - Drug Profile
    • D-4F - Drug Profile
    • DIAS-2 - Drug Profile
    • Dipep - Drug Profile
    • Drug for Atherosclerosis - Drug Profile
    • Drug for Atherosclerosis - Drug Profile
    • Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
    • DWJ-210 - Drug Profile
    • DYB-186 - Drug Profile
    • EP-80317 - Drug Profile
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
    • Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile
    • Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile
    • Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile
    • Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile
    • GKT-831 - Drug Profile
    • GYY-4137 - Drug Profile
    • Humanin - Drug Profile
    • INV-88 - Drug Profile
    • ISIS-APOARx - Drug Profile
    • ITP-01 - Drug Profile
    • ixmyelocel-T - Drug Profile
    • JD-2000 Series - Drug Profile
    • JD-5000 Series - Drug Profile
    • JD-6000 Series - Drug Profile
    • K-312 - Drug Profile
    • K-877 - Drug Profile
    • KM-011 - Drug Profile
    • leucine + niacin - Drug Profile
    • LJPC-6417 - Drug Profile
    • LPC-01 - Drug Profile
    • MCS-18 - Drug Profile
    • MDCO-216 - Drug Profile
    • melittin - Drug Profile
    • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
    • Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile
    • Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile
    • Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile
    • Oligonucleotides to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile
    • P-16 - Drug Profile
    • PC-mAb - Drug Profile
    • Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile
    • PR-15 - Drug Profile
    • Recombinant Protein for Atherosclerosis - Drug Profile
    • Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile
    • Recombinant Protein for Cardiovascular Diseases - Drug Profile
    • Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
    • rPAI-123 - Drug Profile
    • Small Molecule for Atherosclerosis - Drug Profile
    • Small Molecule for Atherosclerosis - Drug Profile
    • Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
    • Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
    • Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile
    • Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
    • Small Molecule to Inhibit microRNA-223 for Atherosclerosis - Drug Profile
    • Small Molecule to Target GPR132 for Cardiovascular Diseases - Drug Profile
    • Small Molecule to Target GPR176 for Atherosclerosis - Drug Profile
    • Small Molecules for Atherosclerosis - Drug Profile
    • Small Molecules for Atherosclerosis, Inflammation and Metabolic Disorders - Drug Profile
    • Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile
    • Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile
    • Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile
    • SPX-7233801 - Drug Profile
    • SR-9009 - Drug Profile
    • Stem Cell Therapy for Atherosclerosis - Drug Profile
    • Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile
    • Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
    • Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile
    • Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile
    • Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile
    • Vaccine for Atherosclerosis - Drug Profile
    • Vaccine for Atherosclerosis - Drug Profile
    • Vaccine for Atherosclerosis - Drug Profile
    • VB-201 - Drug Profile
    • VTP-4 - Drug Profile
  • Atherosclerosis - Recent Pipeline Updates
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Atherosclerosis, H1 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
  • Atherosclerosis - Pipeline by advanceCor GmbH, H1 2016
  • Atherosclerosis - Pipeline by AFFiRiS AG, H1 2016
  • Atherosclerosis - Pipeline by Amgen Inc., H1 2016
  • Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2016
  • Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2016
  • Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2016
  • Atherosclerosis - Pipeline by AtheroNova Inc., H1 2016
  • Atherosclerosis - Pipeline by Bayer AG, H1 2016
  • Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2016
  • Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2016
  • Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Atherosclerosis - Pipeline by CohBar, Inc., H1 2016
  • Atherosclerosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Atherosclerosis - Pipeline by DoNatur GmbH, H1 2016
  • Atherosclerosis - Pipeline by Dybly AG, H1 2016
  • Atherosclerosis - Pipeline by Exicure, Inc., H1 2016
  • Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2016
  • Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2016
  • Atherosclerosis - Pipeline by Johnson & Johnson, H1 2016
  • Atherosclerosis - Pipeline by KineMed, Inc., H1 2016
  • Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2016
  • Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H1 2016
  • Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2016
  • Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2016
  • Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H1 2016
  • Atherosclerosis - Pipeline by Omeros Corporation, H1 2016
  • Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2016
  • Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Atherosclerosis - Pipeline by Resverlogix Corp., H1 2016
  • Atherosclerosis - Pipeline by The Medicines Company, H1 2016
  • Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Atherosclerosis - Pipeline by Tolerys SA, H1 2016
  • Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2016
  • Atherosclerosis - Pipeline by Vericel Corporation, H1 2016
  • Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016
  • Atherosclerosis - Pipeline by XBiotech USA, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Atherosclerosis - Dormant Projects, H1 2016
  • Atherosclerosis - Dormant Projects (Contd..1), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..2), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..3), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..4), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..5), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..6), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..7), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..8), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..9), H1 2016
  • Atherosclerosis - Dormant Projects (Contd..10), H1 2016
  • Atherosclerosis - Discontinued Products, H1 2016
  • Atherosclerosis - Discontinued Products (Contd..1), H1 2016
  • Atherosclerosis - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Atherosclerosis, H1 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top